One such agent, PIT565 (CD19/CD3/CD2), demonstrated enhanced T-cell proliferation, cytokine production, and tumor lysis in preclinical models compared to bispecific antibodies, and showed sustained immune synapse formation and overcoming of T-cell exhaustion [66]. Here, CD19 is linked to neoplasm.